Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Molecular testing to optimize therapeutic decision making in advanced colorectal cancer.

Semrad TJ, Kim EJ.

J Gastrointest Oncol. 2016 Apr;7(Suppl 1):S11-20. doi: 10.3978/j.issn.2078-6891.2015.094. Review.

2.

Excision Repair Cross-complementation Group 1 is a Prognostic Biomarker in Patients with Colorectal Cancer Receiving Chemotherapy.

Li MX, Bi XY, Zhao H, Huang Z, Han Y, Zhao DB, Zhao JJ, Cai JQ.

Chin Med J (Engl). 2016 Mar 5;129(5):586-93. doi: 10.4103/0366-6999.176993.

3.

ERCC1 as a Predictive Marker for FOLFOX Chemotherapy in an Adjuvant Setting.

Kim CY, Seo SH, An MS, Kim KH, Bae KB, Hwang JW, Kim JH, Kim BM, Kang MS, Oh MK, Hong KH.

Ann Coloproctol. 2015 Jun;31(3):92-7. doi: 10.3393/ac.2015.31.3.92. Epub 2015 Jun 30.

4.

MicroRNA-520g confers drug resistance by regulating p21 expression in colorectal cancer.

Zhang Y, Geng L, Talmon G, Wang J.

J Biol Chem. 2015 Mar 6;290(10):6215-25. doi: 10.1074/jbc.M114.620252. Epub 2015 Jan 23.

5.

ERCC1 Induction after Oxaliplatin Exposure May Depend on KRAS Mutational Status in Colorectal Cancer Cell Line: In Vitro Veritas.

Orlandi A, Di Salvatore M, Bagalà C, Basso M, Strippoli A, Plastino F, Calegari MA, Cassano A, Astone A, Barone C.

J Cancer. 2015 Jan 1;6(1):70-81. doi: 10.7150/jca.10478. eCollection 2015.

6.

Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy.

Maus MK, Hanna DL, Stephens CL, Astrow SH, Yang D, Grimminger PP, Loupakis F, Hsiang JH, Zeger G, Wakatsuki T, Barzi A, Lenz HJ.

Pharmacogenomics J. 2015 Aug;15(4):354-62. doi: 10.1038/tpj.2014.73. Epub 2014 Dec 23.

7.
8.
9.

RNA-seq identifies determinants of oxaliplatin sensitivity in colorectal cancer cell lines.

Li XX, Peng JJ, Liang L, Huang LY, Li DW, Shi DB, Zheng HT, Cai SJ.

Int J Clin Exp Pathol. 2014 Jun 15;7(7):3763-70. eCollection 2014.

10.

Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.

Panczyk M.

World J Gastroenterol. 2014 Aug 7;20(29):9775-827. doi: 10.3748/wjg.v20.i29.9775. Review.

11.

Measuring ERCC1 protein expression in cancer specimens: validation of a novel antibody.

Smith DH, Fiehn AM, Fogh L, Christensen IJ, Hansen TP, Stenvang J, Nielsen HJ, Nielsen KV, Hasselby JP, Brünner N, Jensen SS.

Sci Rep. 2014 Mar 7;4:4313. doi: 10.1038/srep04313.

12.

Combination of TRAP1 and ERCC1 Expression Predicts Clinical Outcomes in Metastatic Colorectal Cancer Treated with Oxaliplatin/5-Fluorouracil.

Han JJ, Baek SK, Lee JJ, Kim GY, Kim SY, Lee SH.

Cancer Res Treat. 2014 Jan;46(1):55-64. doi: 10.4143/crt.2014.46.1.55. Epub 2014 Jan 15.

13.

An explorative analysis of ERCC1-19q13 copy number aberrations in a chemonaive stage III colorectal cancer cohort.

Smith DH, Christensen IJ, Jensen NF, Markussen B, Müller S, Nielsen HJ, Brünner N, Nielsen KV.

BMC Cancer. 2013 Oct 21;13:489. doi: 10.1186/1471-2407-13-489.

14.

Polymorphisms of GSTP1, ERCC2 and TS-3'UTR are associated with the clinical outcome of mFOLFOX6 in colorectal cancer patients.

Kumamoto K, Ishibashi K, Okada N, Tajima Y, Kuwabara K, Kumagai Y, Baba H, Haga N, Ishida H.

Oncol Lett. 2013 Sep;6(3):648-654. Epub 2013 Jul 15.

15.

Differential expression and prognostic value of ERCC1 and thymidylate synthase in resected gastric adenocarcinoma.

Squires MH 3rd, Fisher SB, Fisher KE, Patel SH, Kooby DA, El-Rayes BF, Staley CA 3rd, Farris AB 3rd, Maithel SK.

Cancer. 2013 Sep 1;119(17):3242-50. doi: 10.1002/cncr.28175. Epub 2013 May 29.

16.
17.

Glutathione S-transferase Pi expression predicts response to adjuvant chemotherapy for stage C colon cancer: a matched historical control study.

Jankova L, Robertson G, Chan C, Tan KL, Kohonen-Corish M, Fung CL, Clarke C, Lin BP, Molloy M, Chapuis PH, Bokey L, Dent OF, Clarke SJ.

BMC Cancer. 2012 May 28;12:196. doi: 10.1186/1471-2407-12-196.

18.

Prognostic role of ERCC1 in advanced non-small-cell lung cancer: a systematic review and meta-analysis.

Roth JA, Carlson JJ.

Clin Lung Cancer. 2011 Nov;12(6):393-401. doi: 10.1016/j.cllc.2011.04.005. Epub 2011 Jul 1. Review.

19.

Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin.

Gordon MA, Zhang W, Yang D, Iqbal S, El-Khouiery A, Nagashima F, Lurje G, Labonte M, Wilson P, Sherrod A, Ladner RD, Lenz HJ.

Pharmacogenomics. 2011 Jan;12(1):27-39. doi: 10.2217/pgs.10.163.

20.

Comparison of thymidine phosphorylase expression and prognostic factors in gallbladder and bile duct cancer.

Won HS, Lee MA, Chung ES, Kim DG, You YK, Hong TH, Lee IS.

BMC Cancer. 2010 Oct 19;10:564. doi: 10.1186/1471-2407-10-564.

Items per page

Supplemental Content

Write to the Help Desk